Download PDF

This activity is no longer available for credit, however its content is still (may still be) relevant for your educational needs.

Valid: July 26th, 2010 - July 26th, 2011

Statement of Need
The purpose of this activity is to enhance competence concerning the treatment of patients with multiple myeloma.


Target Audience
This activity was developed for pharmacists.


Learning Objectives
At the completion of this activity participants should be able to:

  • Explain the pharmacology and anticancer activity of novel, targeted agents that are expanding therapy for multiple myeloma
  • Discuss the sequencing, dosing, potential interactions, and adverse events of drug regimens administered for multiple myeloma
  • Define how ongoing assessment of patients will ensure integration of drug therapy with stem cell transplantation and other treatment options for patients with multiple myeloma


Registered Pharmacy Designation
MLI is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Completion of this activity provides for 1.0 contact hour (0.1 CEU) of continuing education credit. The universal program number for this activity is 0468-9999-10-021-H01-P.

Disclosure Statement
Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with the manufacturer(s) of any commercial products(s) to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers’ bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and Center of Excellence Media, LLC, do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CE activity for any amount during the past 12 months.


Faculty Disclosures
Casey Williams, PharmD, BCOP, is a consultant to Millennium and has received research support from Novartis.

Leigh Casey, PharmD, is on the advisory board committee for Genzyme.

Laure DuBois, PharmD, is on the advisory board committee for Genzyme.

*Content will include non-FDA-approved uses.


The information provided in this CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.

Related Items
Considerations in Multiple Myeloma: Health Economics
Sagar Lonial, MD, Sandra E. Kurtin, RN, MS, AOCN, ANP-C, Jessica Freels, PharmD, Laureen Kenealy, PharmD, Jacob Kettle, PharmD, Casey Williams, PharmD, BCOP
Supplements published on October 31, 2008
Last modified: March 21, 2014